Stock listing

NASDAQ:JANX Janux Therapeutics, Inc. Stock

Home listing (NASDAQ) of Janux Therapeutics, Inc.

Follow Janux Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:JANX

$10.08 USD -0.23 (-2.2%)

Close on Nov 20, 2026

Past year -64.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$10.05 – $10.54 USDNov 20, 2026
Volume
1.11M sharesNov 20, 2026
Market cap
$616.7M USDAt the close on Nov 20, 2026 · price × 61.18M shares outstanding
52-week range
$10.05 – $35.34 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$15.74M USDMedian day 810,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Janux Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:JANX · Home$10.08 USD-0.23 (-2.2%)1,114,707$10.16$10.54$10.05$10.31Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:JANX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$10.08-0.23-2.2%$10.16$10.54$10.051,114,707
$10.31-0.40-3.7%$10.69$10.82$10.21980,519
$10.71-0.21-1.9%$10.90$11.01$10.50733,702
$10.92-0.45-4.0%$11.28$11.32$10.73786,664
$11.37-0.125-1.1%$11.49$11.56$11.16717,851
$11.50-0.895-7.2%$11.86$11.99$11.451,168,638
$12.39+0.35+2.9%$12.05$12.77$11.971,189,495
$12.04-0.72-5.6%$12.75$12.76$11.592,354,815
$12.76-4.87-27.6%$17.95$17.95$12.434,848,775
$17.63+1.57+9.8%$16.77$17.81$16.14852,300
$16.06-2.12-11.7%$18.18$18.24$16.02893,100
$18.18+0.36+2.0%$18.19$18.33$17.43976,200
$17.82+0.36+2.1%$17.60$18.00$17.59769,300
$17.46-0.01-0.1%$17.50$17.82$17.40412,700
$17.47-0.36-2.0%$17.93$18.17$17.13540,000
$17.83-0.22-1.2%$18.18$18.62$17.70903,500
$18.05+0.79+4.6%$17.01$18.07$16.89984,100
$17.26+0.57+3.4%$16.68$17.63$16.42687,200
$16.69+0.03+0.2%$16.80$17.18$16.51379,200
$16.66-0.40-2.3%$16.94$16.94$16.27378,900
$17.06+0.13+0.8%$16.88$17.26$16.58514,200
$16.93-0.27-1.6%$17.22$17.47$16.79587,400
$17.20+0.46+2.7%$16.80$17.66$16.72869,400
$16.74+0.23+1.4%$16.61$16.87$16.46915,100
$16.51-0.81-4.7%$17.27$17.27$16.43765,900
$17.32+0.19+1.1%$17.30$17.62$17.02546,900
$17.13-0.05-0.3%$17.13$17.49$16.84614,600
$17.18-0.97-5.3%$18.06$18.14$16.97794,900
$18.15-0.24-1.3%$18.29$18.61$17.96803,000
$18.39-0.11-0.6%$18.42$19.18$18.321,173,000
$18.50+0.58+3.2%$17.77$18.90$17.301,500,800
$17.92+1.13+6.7%$16.52$18.37$16.421,210,200
$16.79+0.25+1.5%$16.69$17.37$16.31809,800
$16.54-0.39-2.3%$16.93$16.95$16.13533,700
$16.93-0.03-0.2%$17.25$17.29$16.84805,300
$16.96-0.32-1.9%$17.20$17.35$16.76837,500
$17.28+0.33+1.9%$17.08$17.56$16.79772,500
$16.95+0.37+2.2%$16.54$16.98$16.32511,700
$16.58+0.28+1.7%$16.57$16.79$16.16473,000
$16.30-0.38-2.3%$16.62$16.70$16.21720,200
$16.68+0.16+1.0%$16.42$16.79$15.751,302,000
$16.52-0.95-5.4%$17.40$17.47$16.35967,400
$17.47+0.46+2.7%$17.17$17.47$16.97908,300
$17.01+0.42+2.5%$16.86$17.14$16.53701,800
$16.59-0.27-1.6%$16.70$16.86$16.402,447,400
$16.86+0.615+3.8%$16.49$17.22$16.49810,000
$16.25-0.195-1.2%$16.43$16.61$16.041,161,600
$16.44-0.87-5.0%$17.29$17.29$16.301,008,500
$17.31+0.21+1.2%$17.13$17.57$17.13869,800
$17.10-0.58-3.3%$17.92$17.94$17.05791,400
$17.68-1.65-8.5%$19.17$19.33$17.60980,000
$19.33-0.71-3.5%$19.94$20.23$19.27576,000
$20.04-0.20-1.0%$20.24$20.25$19.671,061,700
$20.24+0.44+2.2%$19.62$20.31$19.57700,800
$19.80+0.10+0.5%$19.73$20.00$19.521,686,600
$19.70+0.81+4.3%$18.93$19.95$18.931,525,600
$18.89+0.67+3.7%$18.15$18.94$18.04980,500
$18.22+0.19+1.1%$17.89$18.39$17.66712,600
$18.03-0.75-4.0%$18.57$18.73$17.97637,800
$18.78-0.11-0.6%$19.00$19.08$18.68577,300
$18.89+0.21+1.1%$18.59$18.95$18.33524,000
$18.68+0.08+0.4%$18.72$19.14$18.551,074,447
$18.60+1.21+7.0%$17.82$19.03$17.501,452,369
$17.39+0.11+0.6%$17.40$17.70$17.21520,000
$17.28-0.24-1.4%$17.29$17.64$17.191,121,800
Ticker
NASDAQ:JANX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Janux Therapeutics, Inc. news

Janux Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 74 in all · newest Nov 9, 2026 · oldest 2021
Decks
9 decks · latest November 2026

Where Janux Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:JANX · Home listing · This pageNASDAQUnited StatesUSD
BX Swiss:JANXBX SwissSwitzerlandCHF
BOATS:JANXBOATSUnited StatesUSD

Valuation

EV/sales −13.3× against a median of 37.8×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$308.6M USD
P/E
Loss
EV/sales
−13.3×
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
−78.7%
Operating margin
−599.3%
Net margin
−428.7%
Debt to equity
0.0×
Beta vs S&P 500
0.95

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Janux Therapeutics, Inc. · NASDAQ:JANXUS$616.7M−US$308.6Mn/a−13.3×n/a0.7×−428.7%0.0×0.95
Shouyao Holdings Beijing Co. Ltd. Class A · SSE:688197US$647.2MUS$565.0Mn/a37.8×n/a6.8×−18.6%0.0×n/a
Prime Medicine, Inc. · NASDAQ:PRMEUS$645.8MUS$695.1Mn/a98.4×n/a76.5×n/a13.1×2.28
Sagimet Biosciences Inc. - Series A · NASDAQ:SGMTUS$638.7MUS$404.3Mn/an/an/a2.6×n/a0.0×1.96
Gubra A/S · OMXCOP:GUBRAUS$638.5MUS$533.6M2.6×1.4×1.7×4.2×64.1%0.2×n/a
Kura Oncology, Inc. · NASDAQ:KURAUS$634.9MUS$152.6Mn/a1.9×n/a35.4×−369.3%0.6×1.30
Alphamab Oncology · HKEX:9966US$628.9MUS$454.7Mn/a5.5×n/a2.5×−20.1%0.2×n/a
Iambic Therapeutics, Inc. · NASDAQ:IAMUS$621.4MUS$369.4Mn/a39.2×n/an/a−820.0%n/an/a
Olema Pharmaceuticals, Inc. · NASDAQ:OLMAUS$615.0MUS$204.6Mn/an/an/a1.7×n/a0.0×1.25
Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637US$608.9MUS$483.6Mn/a106×n/a2.9×n/a0.4×n/a
Annexon, Inc. · NASDAQ:ANNXUS$587.7MUS$423.7Mn/an/an/a4.1×n/a0.3×1.63
Median of the othersUS$631.9MUS$439.2M2.6×37.8×1.7×4.1×−20.1%0.2×1.63

Forecasts

13 strong buy · 2 buy · 2 hold · 1 sell · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
33.14 USD · Analysts' mean
EPS, year to Dec 2026
-1.57 · 15 analysts
Revenue, year to Dec 2026
27.49M · 14 analysts

Team and board

Officers

OfficerRole
David CampbellFounder, President & Chief Executive Officer
Matt WhitmireVice President, Finance
James PenningtonGeneral Counsel
Carolina CaffaroVice President, CMC Process Development
Gregory OpiteckVice President, Translational Medicine
Jenna DalyVice President, Clinical Operations
Jonathan LeithVice President, Project Leadership
Judy VongVice President, Regulatory Affairs and Quality Assurance
Kevin WattVice President, Program and Portfolio Management
Maria DobekVice President, Accounting
Simon ButikoferVice President, Clinical Development
Janeen DoyleChief Corporate and Business Development Officer
Mandie Forman-SklanskyHead of Human Resources
Tommy DiRaimondoChief Scientific Officer
William GoChief Medical Officer

Board

DirectorRole
Ron BarrettChairperson
David CampbellFounder, President & Chief Executive Officer
Eric Dobmeier
Jake Simson
Natasha Hernday
Vickie Capps
Winston Kung

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+9.8%
Q2 2026Aug 6, 2026 · After close−1.6%
Q1 2026May 7, 2026 · After close−2.5%
Q4 2025Feb 26, 2026−0.7%
Q3 2025Nov 6, 2025 · After close−7.6%
Q2 2025Aug 7, 2025 · After close+1.1%
Q1 2025May 8, 2025 · After close−3.1%
Q4 2024Feb 27, 2025+0.9%
Q3 2024Nov 6, 2024 · After close−1.2%
Q2 2024Aug 7, 2024 · After close+3.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · After close−10.0%
Q4 2023Mar 8, 2024 · After close+0.4%
Q3 2023Nov 7, 2023 · After close+0.9%
Q2 2023Aug 8, 2023 · After close+6.8%
Q1 2023May 9, 2023 · After close+4.0%
Q4 2022Mar 10, 2023 · After close−2.3%
Q3 2022Nov 10, 2022 · After close+5.8%
Q2 2022Aug 9, 2022 · After close+11.9%
Q1 2022May 10, 2022 · After close+1.0%
Q4 2021Mar 18, 2022 · After close−9.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck20 slidesNovember 2026
Cantor Global Healthcare Conference 2026Conference21 slidesSep 11, 2026
Technical Presentation (December 2025)Technical26 slidesDec 1, 2025
Investor Day (July 2025)Investor day41 slidesJul 24, 2025
Corporate Update (December 2024)Corporate update25 slidesDec 2, 2024
Investor Presentation (March 2024)Investor deck36 slidesMarch 2024
Investor Presentation (February 2024)Investor deck31 slidesFeb 26, 2024
Investor Presentation (February 2024)Investor deck34 slidesFeb 26, 2024
Corporate Update (July 2023)Corporate update19 slidesJul 17, 2023

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Closed: US$402.5M raised · US$63 a share · BofA Securities +8
Dealers: BofA Securities (co-lead), TD Cowen (co-lead), Stifel (co-lead), Cantor (co-lead), William Blair (co-lead), Wedbush PacGrow, LifeSci Capital, BTIG, Jones
Use of proceeds: Advance clinical development of its internal product pipeline and general corporate purposes
Dec 6, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Jun 10, 2021.

Price
US$17.00 a share
Shares offered
11,400,000 shares of common stock
Offering size
US$193.8 million
Underwriters' option
Up to 1,710,000 more shares
Underwriters
BofA Securities, Cowen, Evercore ISI, H.C. Wainwright & Co. · In the order on the cover
Shares delivered
On or about Jun 15, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceApr 16, 2021
Filed publiclyMay 19, 2021
Amended onceJun 7, 2021
Shares registered with an exchangeJun 9, 2021
Declared effective by the SECJun 10, 2021
Final prospectus, with the priceJun 11, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jun 11, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue10.0M10.6M8.08M8.61M3.64M00
Cost of revenue2.03M2.06M1.96M75.7M36.6M13.0K6.00K
Gross profit7.97M8.53M6.13M8.61M3.64M-13.0K-6.00K
Research and development125.9M68.4M54.9M53.4M26.2M3.04M3.00M
Selling, general and administrative41.8M41.0M26.1M22.3M10.3M1.80M772.0K
Operating income-157.7M-98.8M-73.0M-67.1M-32.9M-4.84M-3.77M
Depreciation and amortization2.03M2.06M1.96M841.0K113.0K13.0K6.00K
EBITDA-155.6M-96.8M-71.0M-66.3M-32.8M-4.83M-3.77M
Interest expense4.03M370.0K206.0K233.0K
Income before tax-113.6M-69.0M-58.3M-63.1M-32.7M-6.78M-4.00M
Income tax000-8.90M-113.0K-1.53M233.0K
Net income-113.6M-69.0M-58.3M-63.1M-32.7M-6.78M-4.24M
Earnings per share, basic-1.83-1.28-1.32-1.52-1.39-7.41-0.10
Earnings per share, diluted-1.83-1.28-1.32-1.52-1.39-7.41

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents52.3M430.6M19.2M51.4M35.6M7.81M658.0K
Short-term investments914.2M594.6M324.8M275.6M339.4M0
Receivables05.38M0008.00M0
Inventory-2.20M-700.0K-200.0K
Current assets975.9M1.03B349.2M332.4M377.0M16.1M658.0K
Property, plant and equipment3.85M4.86M7.00M7.09M1.41M155.0K21.0K
Total assets1.00B1.06B380.4M364.0M379.8M16.2M679.0K
Accounts payable4.97M4.03M2.42M2.16M2.46M428.0K267.0K
Current liabilities25.0M17.5M13.0M16.5M12.8M3.18M4.63M
Total debt22.1M23.0M24.5M25.3M194.0K4.00M
Total liabilities44.7M38.7M36.1M43.3M13.5M9.23M8.62M
Shareholders' equity956.8M1.02B344.3M320.7M366.3M-14.6M-7.94M
Shares outstanding60.4M59.1M46.3M41.6M41.2M1.05M41.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-82.2M-43.8M-50.6M-42.9M-17.0M-4.37M-3.83M
Capital spending-1.04M-359.0K-1.85M-6.45M-1.48M0-1.48M
Free cash flow-83.3M-44.2M-52.4M-49.4M-18.5M-4.37M-3.83M
Cash from investing-301.0M-258.0M-41.2M58.3M-341.0M0-341.0M
Cash from financing4.95M713.2M59.5M500.0K386.5M11.5M4.00M
Share buybacks-347.0K204.2M
Change in cash-378.3M411.4M-32.2M15.8M28.6M7.16M172.0K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 31, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 28, 2026Big-stake noticeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJun 23, 2026Current reportSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 12, 2026Meeting outcomeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
144 · Notice of proposed saleJun 2, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
8-K · Current reportApr 28, 2026Management or board changeSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
144 · Notice of proposed saleApr 13, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 6, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
144 · Notice of proposed saleJan 26, 2026Other filingsSEC
144 · Notice of proposed saleJan 23, 2026Other filingsSEC
8-K · Current reportJan 22, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 8, 2026Big-stake noticeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
144 · Notice of proposed saleDec 2, 2025Other filingsSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
144 · Notice of proposed saleNov 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
144 · Notice of proposed saleOct 28, 2025Other filingsSEC
8-K · Current reportSep 19, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 23, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
144 · Notice of proposed saleMay 1, 2025Other filingsSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
4 · Change in ownershipApr 23, 2025Insider tradeSEC
144 · Notice of proposed saleApr 21, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 10, 2025Big-stake noticeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 3, 2025Other filingsSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
144 · Notice of proposed saleJan 7, 2025Other filingsSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
3/A · Initial statement of ownership, amendedJan 3, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
4 · Change in ownershipDec 27, 2024Insider tradeSEC
144 · Notice of proposed saleDec 26, 2024Other filingsSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
8-K · Current reportDec 5, 2024Current reportSEC
424B5 · ProspectusDec 5, 2024Offer documentSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
424B5 · ProspectusDec 3, 2024Offer documentSEC
8-K · Current reportDec 2, 2024Current reportSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
4 · Change in ownershipNov 7, 2024Insider tradeSEC
4 · Change in ownershipNov 7, 2024Insider tradeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
144 · Notice of proposed saleNov 1, 2024Other filingsSEC
144 · Notice of proposed saleNov 1, 2024Other filingsSEC
144 · Notice of proposed saleNov 1, 2024Other filingsSEC
144 · Notice of proposed saleNov 1, 2024Other filingsSEC
144 · Notice of proposed saleNov 1, 2024Other filingsSEC
144 · Notice of proposed saleNov 1, 2024Other filingsSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
144 · Notice of proposed saleOct 28, 2024Other filingsSEC
144 · Notice of proposed saleOct 28, 2024Other filingsSEC
144 · Notice of proposed saleOct 28, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedOct 25, 2024Big-stake noticeSEC
144 · Notice of proposed saleOct 25, 2024Other filingsSEC
144 · Notice of proposed saleOct 25, 2024Other filingsSEC
144 · Notice of proposed saleOct 25, 2024Other filingsSEC
144/A · Notice of proposed sale, amendedOct 25, 2024Other filingsSEC
144 · Notice of proposed saleOct 24, 2024Other filingsSEC
144 · Notice of proposed saleOct 24, 2024Other filingsSEC
4 · Change in ownershipOct 24, 2024Insider tradeSEC
144 · Notice of proposed saleOct 23, 2024Other filingsSEC
SC 13G · Big-stake noticeOct 23, 2024Big-stake noticeSEC
144 · Notice of proposed saleOct 23, 2024Other filingsSEC
144 · Notice of proposed saleOct 23, 2024Other filingsSEC
144 · Notice of proposed saleOct 23, 2024Other filingsSEC
4 · Change in ownershipOct 22, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedOct 22, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedOct 22, 2024Big-stake noticeSEC
144 · Notice of proposed saleOct 21, 2024Other filingsSEC
144 · Notice of proposed saleOct 21, 2024Other filingsSEC
144 · Notice of proposed saleOct 21, 2024Other filingsSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
144 · Notice of proposed saleOct 18, 2024Other filingsSEC
144 · Notice of proposed saleOct 18, 2024Other filingsSEC
144 · Notice of proposed saleOct 18, 2024Other filingsSEC
144 · Notice of proposed saleOct 17, 2024Other filingsSEC
144 · Notice of proposed saleOct 17, 2024Other filingsSEC
144 · Notice of proposed saleOct 17, 2024Other filingsSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
144 · Notice of proposed saleSep 30, 2024Other filingsSEC
144 · Notice of proposed saleSep 30, 2024Other filingsSEC
144 · Notice of proposed saleSep 30, 2024Other filingsSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
144 · Notice of proposed saleSep 27, 2024Other filingsSEC
144 · Notice of proposed saleSep 26, 2024Other filingsSEC
144 · Notice of proposed saleSep 26, 2024Other filingsSEC
144 · Notice of proposed saleSep 26, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedSep 16, 2024Big-stake noticeSEC

This page holds 200 of 443 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Janux Therapeutics, Inc.’s releases · as of Nov 3, 2026

Common shares
61,183,417
Fully diluted
61,183,417

Fully diluted

LineSharesAs of
Common shares61,183,417Nov 3, 2026

Share count over time

CountShares
Nov 3, 202661,183,417

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Ra Capital Management, L.P.11.2MUS$193MSep 30, 2026
BlackRock6.53MUS$113MSep 30, 2026
Vanguard4.01MUS$69.3MSep 30, 2026
Prosight Management, LP2.94MUS$50.9MSep 30, 2026
Federated Hermes, Inc.2.59MUS$44.8MSep 30, 2026
Fidelity2.51MUS$43.4MSep 30, 2026
State Street2.31MUS$39.9MSep 30, 2026
Two Sigma1.85MUS$31.9MSep 30, 2026
TCG Crossover Management, LLC1.79MUS$30.9MSep 30, 2026
Point72 Asset Management, L.P.1.58MUS$27.3MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
D. E. Shaw & Co., Inc.1.51MUS$26.1MSep 30, 2026
Algert Global LLC1.42MUS$24.6MSep 30, 2026
Geode Capital1.28MUS$22.1MSep 30, 2026
Alyeska Investment Group, L.P.1.1MUS$18.9MSep 30, 2026
Nuveen1.04MUS$18.1MSep 30, 2026
Goldman Sachs1.03MUS$17.7MSep 30, 2026
Morgan Stanley962KUS$16.6MSep 30, 2026
Wellington921KUS$15.9MSep 30, 2026
Nantahala Capital Management, LLC857KUS$14.8MSep 30, 2026
ADAR1 Capital Management, LLC824KUS$14.2MSep 30, 2026
Ameriprise749KUS$12.9MSep 30, 2026
Qube Research & Technologies Ltd647KUS$11.2MSep 30, 2026
Orbimed Advisors LLC525KUS$9.07MSep 30, 2026
Bank of America506KUS$8.75MSep 30, 2026
Citadel497KUS$8.58MSep 30, 2026
Hrt Financial LP445KUS$7.69MSep 30, 2026
Schwab442KUS$7.64MSep 30, 2026
Dimensional441KUS$7.63MSep 30, 2026
Northern Trust417KUS$7.2MSep 30, 2026
Squarepoint Ops LLC391KUS$6.75MSep 30, 2026
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.376KUS$6.51MSep 30, 2026
Woodline Partners LP372KUS$6.42MSep 30, 2026
Rock Springs Capital Management LP367KUS$6.34MSep 30, 2026
Jump Financial, LLC345KUS$5.95MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.312KUS$5.39MSep 30, 2026
AQR Capital Management LLC250KUS$4.32MSep 30, 2026
UBS250KUS$4.32MSep 30, 2026
Panagora Asset Management Inc223KUS$3.85MSep 30, 2026
Millennium219KUS$3.79MSep 30, 2026
Squadron Capital Management LLC215KUS$3.72MSep 30, 2026
Allspring Global Investments Holdings, LLC209KUS$3.54MSep 30, 2026
Balyasny Asset Management L.P.208KUS$3.6MSep 30, 2026
Quantinno Capital Management LP207KUS$3.57MSep 30, 2026
JPMorgan174KUS$2.95MSep 30, 2026
Creative Planning168KUS$2.91MSep 30, 2026
Man Group plc161KUS$2.78MSep 30, 2026
BML Capital Management, LLC151KUS$2.61MSep 30, 2026
BNY142KUS$2.46MSep 30, 2026
Russell Investments Group, Ltd.138KUS$2.38MSep 30, 2026
Franklin Templeton133KUS$2.42MSep 30, 2026

This page holds 50 of 197 holders. Open Shareholders

Funds

HolderSharesValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF1.93MUS$29.6MJun 30, 2026
Federated Hermes MDT Small Cap Core Fund1.37MUS$20.8MJul 31, 2026
Vanguard Total Stock Market Index Fund1.26MUS$19.4MJun 30, 2026
iShares Russell 2000 ETF1.13MUS$17.3MJun 30, 2026
Vanguard Extended Market Index Fund552KUS$8.48MJun 30, 2026
Fidelity Small Cap Index Fund471KUS$7.15MJul 31, 2026
Vanguard Strategic Equity Fund424KUS$6.51MJun 30, 2026
iShares Russell 2000 Value ETF405KUS$6.23MJun 30, 2026
iShares Biotechnology ETF404KUS$6.2MJun 30, 2026
Nuveen Quant Small Cap Equity Fund381KUS$5.78MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
BlackRock Advantage Small Cap Core Fund381KUS$5.55MMay 29, 2026
Federated Hermes MDT Small Cap Growth Fund376KUS$5.71MJul 31, 2026
Bridge Builder Small/Mid Cap Growth Fund341KUS$5.23MJun 30, 2026
Fidelity Series Small Cap Core Fund329KUS$4.98MJul 31, 2026
Vanguard Explorer Fund326KUS$4.95MJul 31, 2026
Fidelity Advisor Biotechnology Fund320KUS$4.86MJul 31, 2026
Fidelity Extended Market Index Fund251KUS$3.67MMay 31, 2026
Fidelity Blue Chip Growth Fund231KUS$3.5MJul 31, 2026
Schwab U.S. Small-Cap ETF229KUS$3.35MMay 31, 2026
Vanguard Russell 2000 Index Fund220KUS$3.22MMay 31, 2026
Select Biotechnology Portfolio207KUS$3.02MMay 31, 2026
North Square Dynamic Small Cap Fund163KUS$2.37MMay 31, 2026
Small Cap Equity Fund154KUS$2.36MJun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund146KUS$2.13MMay 31, 2026
iShares Genomics Immunology and Healthcare ETF124KUS$1.88MJul 31, 2026
Fidelity Blue Chip Growth ETF123KUS$1.87MJul 31, 2026
Dimensional U.S. Small Cap ETF123KUS$1.87MJul 31, 2026
U.S. Micro Cap Portfolio119KUS$1.81MJul 31, 2026
Vanguard Strategic Small-Cap Equity Fund118KUS$1.82MJun 30, 2026
Vanguard Health Care Index Fund117KUS$1.71MMay 31, 2026
Allspring Common Stock Fund111KUS$1.71MJun 30, 2026
Schwab Small-Cap Index Fund105KUS$1.59MJul 31, 2026
Small Cap Growth Stock Portfolio103KUS$1.58MJun 30, 2026
Nuveen Quant Small/Mid Cap Equity Fund98,800US$1.5MJul 31, 2026
Federated Hermes MDT Small Cap Value Fund f/k/a Federated Hermes Clover Small Value Fund98,111US$1.51MJun 30, 2026
Fidelity Total Market Index Fund91,364US$1.33MMay 31, 2026
U.S. Small Cap Portfolio86,270US$1.31MJul 31, 2026
Master Small Cap Index Series81,411US$1.25MJun 30, 2026
Nomura Healthcare Fund76,601US$1.18MJun 30, 2026
BlackRock Advantage SMID Cap Fund, Inc.76,510US$1.18MJun 30, 2026
Hartford Small Cap Growth Hls Fund74,279US$1.14MJun 30, 2026
Fidelity Series Total Market Index Fund73,740US$1.08MMay 31, 2026
Strategic Advisers U.S. Total Stock Fund71,770US$1.05MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF68,269US$1.05MJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares65,529US$994KJul 31, 2026
Federated Hermes MDT Small Cap Core ETF62,348US$910KMay 31, 2026
BlackRock Advantage Small Cap Growth Fund60,905US$936KJun 30, 2026
Fidelity Small Cap Value Index Fund60,191US$925KJun 30, 2026
Small Company Growth Portfolio55,497US$852KJun 30, 2026
iShares U.S. Small-Cap Equity Factor ETF52,873US$802KJul 31, 2026

This page holds 50 of 195 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Doyle Janeen Noel
Officer: Chief Corp. & Bus. Dev. Ofcr
Sale4,059USD 14.03US$56,948Jun 2, 2026
Dobek Maria
Officer: Vice President, Accounting
Sale2,038USD 14.17US$28,878May 11, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.19.90%12MMar 6, 2025Schedule 13D
BlackRock, Inc.6.70%4.1MJun 30, 2026Schedule 13G
Prosight Management, LP5.15%3.15MNov 10, 2026Schedule 13G
Janus Henderson Group PLC0.30%172KJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Jun 10, 2021
Vickie Capps
Other companies: Orthofix Medical Inc. (Director · Since at least Mar 11, 2025); Amedisys Inc (Director · Since at least Nov 1, 2019); ARS Pharmaceuticals, Inc. (Director · Dec 3, 2020 – Jun 10, 2022 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); NuVasive Inc (Director · Jun 12, 2015 – Sep 1, 2023 · Past); Connecture Inc (Director · Dec 11, 2014 – Apr 25, 2018 · Past); Otonomy Inc (Director · Aug 12, 2014 – Nov 28, 2022 · Past); Senorx Inc (Director · Jun 14, 2007 – Feb 26, 2010 · Past); Djo Inc (Executive VP, CFO · Jun 28, 2006 – Nov 20, 2007 · Past)
Director · Since at least Jun 10, 2021
Eric Dobmeier
Other companies: Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Structure Therapeutics, Inc. (Director · Since at least Feb 2, 2023); Aduro Biotech Inc (President, CEO, Director · Oct 5, 2020 – Aug 11, 2023 · Past); Atara Biotherapeutics, Inc. (Director · Jun 27, 2019 – Nov 10, 2023 · Past); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Feb 14, 2021 · Past)
Director · Since at least Jul 19, 2024
Winston Kung
Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Since at least Aug 16, 2024); ArriVent BioPharma, Inc. (Chief Financial Officer · Since at least Jan 25, 2024); PMV Pharmaceuticals, Inc. (COO, CFO · Sep 24, 2020 – May 12, 2023 · Past)
Director · Since at least Sep 21, 2022
Jake Simson
Other companies: Septerna, Inc. (Director · Since at least Nov 5, 2026)
Director · Since at least Jun 11, 2026
Natasha Hernday
Other companies: XOMA Royalty Corporation (Director · Since at least May 21, 2026)
Director · Since at least Jun 11, 2026
Andrew Hollman MeyerChief Business Officer · Since at least Jan 2, 2024
Byron RobinsonChief Strategy Officer · Mar 1, 2022 – Jan 2, 2025 · Past
Carolina CaffaroVice President, CMC Process Development · Since at least Nov 5, 2026
Charles M WinterChief Technical Officer · Since at least Jan 2, 2024
All 30 people
PersonSeat
David CampbellFounder, President & Chief Executive Officer · Since at least Jul 31, 2026
Gregory OpiteckVice President, Translational Medicine · Since at least Nov 5, 2026
James PenningtonGeneral Counsel · Since at least Nov 5, 2026
Janeen DoyleChief Corp. & Bus. Dev. Ofcr · Since at least May 14, 2025
Jenna DalyVice President, Clinical Operations · Since at least Nov 5, 2026
Jonathan LeithVice President, Project Leadership · Since at least Nov 5, 2026
Judy VongVice President, Regulatory Affairs and Quality Assurance · Since at least Nov 5, 2026
Kevin WattVice President, Program and Portfolio Management · Since at least Nov 5, 2026
Mandie Forman-SklanskyHead of Human Resources · Since at least Nov 5, 2026
Maria DobekVice President, Accounting · Since at least Aug 8, 2024
Matt WhitmireVice President, Finance · Since at least Nov 4, 2026
Ronald W BarrettDirector · Since at least Jun 11, 2025
Ron BarrettChairperson · Since at least Jun 12, 2026
Simon ButikoferVice President, Clinical Development · Since at least Sep 14, 2026
Stefan HellerDirector · Jun 10, 2021 – Jun 14, 2022 · Past
Thomas DiRaimondoChief Scientific Officer · Since at least Jan 1, 2024
Tommy DiRaimondoChief Scientific Officer · Since at least Feb 17, 2026
Wayne GodfreyChief Medical Officer · Jun 10, 2021 – Jan 3, 2023 · Past
William GoChief Medical Officer · Since at least Jan 26, 2026
Zachariah McIverChief Medical Officer · Since at least Jan 1, 2025

Open People

Log in to ask 6ix AI your own questions about Janux Therapeutics, Inc.